TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
The Bern TAVI Registry looked at 2,500 TAVR patients to determine the level of prosthesis-patient mismatch (PPM) using transthoracic echocardiography (TTE), predicting PPM based one the size of the valve used, or using CT measurements of the aortic annulus to see which was method was most accurate at predicting PPM. Image courtesy of Tomii et al. 

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

November 17, 2023

TAVR linked to favorable outcomes for asymptomatic and minimally symptomatic patients—but is it necessary?

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

November 15, 2023
Doctor patient

TAVR utilization skyrocketed over 5-year period, improving survival for older AS patients

The study focused on patients 65 years old and older who underwent treatment in one of 21 high-income countries. 

November 10, 2023
Medtronic Onyx Frontier DES stent with an enlarged 3D print of the stent used in bifurcation stenting. Photo by Dave Fornell

PHOTO GALLERY: Interventional cardiology technologies at TCT 2023

Browse through some of the many highlights from TCT 2023 in San Francisco.

November 9, 2023
While a vast majority of heart transplants in the United States are successful, unplanned hospitalizations after the procedures are still incredibly common. Top 10 reasons for readmission after heart transplant.

Surgeons warn it is too early to recommend a TAVR-first strategy for low-risk patients

The Society of Thoracic Surgeons and European Association for Cardio-Thoracic Surgery say more information is still required before any conclusions can be made about the long-term benefits of TAVR in low-risk patients.

November 6, 2023
Kendra Grubb discusses TAVR vs SAVR and the most recent data to explain choices with patients.

TAVR or SAVR? Where things stand now, from a surgeon's perspective

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

November 3, 2023
Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

November 2, 2023
Doctor patient

TAVR patients with cancer face higher risks of hospital readmission, serious bleeding

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

November 1, 2023
Displaying 57 - 64 of 336
Design by Adaptive Theme